TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ADHD symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 second stand-up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Countermovement jump test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Eye-hand Coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of adjudicated cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular Hypertrophy - Sokolow-Lyon voltage criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular Hypertrophy - Cornell voltage product criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax (maximum plasma concentration) of PF-06651600
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Area under the curve) of PF-06651600
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of UTI due to MDR bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in exercise-induced oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial injury at 30 days after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Dose-limiting Toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Delirium/Coma Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of hip joint diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in serum vitamin D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freedom from Major Adverse Cardiac Event
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from major arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events (AEs) Attributed to the Investigational Product, arTreg-CSB
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Adverse Events (AEs) Attributed to the Investigational Product, arTreg-CSB
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Operationally Tolerant Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Change in quality of life over time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in medical resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Steady-state Cmax,ss of raltegravir and raltegravir glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state AUC0-12h,ss of raltegravir and raltegravir glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C12h,ss of raltegravir and raltegravir glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopmental follow up at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SBI-087
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Blood Pressure Values Meeting Pre-defined Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values Meeting Pre-defined Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-partum hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Predictive and prognostic value of HE4 marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lung function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Contrast-Induced Nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Initiation of study drug infusion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the Neuron-specific Enolase curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acceptance rate of self-screening for insomnia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appeal scores of flavored versus unflavored cigarillos
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceptions of harm of flavored cigarillos versus unflavored cigarillos
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Abuse liability of flavored cigarillos products versus unflavored cigarillo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HLA-DQB1 06
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with HLA-DRB 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Medical Research Council sum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Inflammatory Rasch-built Overall Disability Scale (I-RODS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Phenytoin metabolic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D 2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: diagnostic value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Initial Engraftment by Day 45
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade II-IV Acute Graft Versus Host Disease (GVHD) by Day 100
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombin-Antithrombin (TAT) Complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-Dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of neurologic paroxystic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gut microbiota changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of cytopemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effectiveness of MKTP in treating vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep (hours per night)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Resting Heart Rate (RHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of BG9924 in combination with methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-Lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of blood loss during cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Skin imaging quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NAb Dose Titer in the Convalescent Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Generalized distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical failure by day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Boston Carpal Tunnel Questionnaire (BCTQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Characteristic sign-and-symptom associations of acromegaly
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30-day postsurgical mortality
Endpoint domain: Mortality/survival
Primary endpoint: 30-day postsurgical infection
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day postsurgical readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Systemic and regional hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Eligible Participants Who Accrue to NDURE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Texture changes of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: peri procedural safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Perception of Depth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Perception of Breathing Gas
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Electroencephalogram (EEG) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HEV blood incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at 168 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in intolerance of uncertainty
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relapse-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in HIV-1 RNA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ) (400 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of HIV-1 RNA levels BLQ (50 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients who Died
Endpoint domain: Mortality/survival
Primary endpoint: Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: COPD Exacerbation Rate (Moderate or Severe)
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of Change in Isokinetic Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of divalproex ER compared to risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of inflammatory bowel disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spontaneous delivery before 34 completed weeks
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to the Physical Activity Guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bypass graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood loss at the end of myomectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: functional and neurodevelopmental outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progressive vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Florbetapir-PET Scan Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Brief Pain Inventory (BPI) Pain Severity Pain at Its Worst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Analgesic Effect as Assessed by Brief Pain Inventory (BPI) Item 5 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary loss frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Extended Barthel Index (EBI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pancreatic tumor conspicuity on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dislocation rate of Medacta Versafit Cup DM
Endpoint domain: Adverse events/effects
Primary endpoint: Implant position fixation and wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient Satisfaction and outcome score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Eyes With Inflammation Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cooling/soothing effect score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Automated cortical auditory evoked potentials results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Speech therapy result
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: The baby's amount of milk intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preoperative glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time from opening of child welfare case to SUD screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in addiction severity among participating parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reunification among families involved in EPIC compared to substance-affected families not receiving EPIC
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sudden Death Mortality
Endpoint domain: Mortality/survival
Primary endpoint: 50% improvement on Hamilton Depression Rating Scale-17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients Surviving Progression-free
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and tolerability of AZD1446
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with normal and elevated Lipoprotein(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in ADAS-Cog total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in sleep outcomes
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Correlation of functional MR parameters with histology results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of functional MR parameters with final clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical quality of the LP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of albumin synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating LPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: H. pylori infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Degree of chronic gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral Blood Basophil Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of at Least 15 Points in ODI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Reoperations, Revisions, Removals, or Supplemental Fixation
Endpoint domain: Adverse events/effects
Primary endpoint: No Major Device Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: ELF and AM/Plasma Ratios of Cmax and AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paediatric Pain Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HbA1c (glycosylated hemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain score in the last 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving therapeutic goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrode psychophysics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological Condition of the Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: frequency of subjects with drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-tz (area under the concentration-time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum measured concentration of the analyte in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity, specificity, and accuracy of PET/MRI at diagnosis of IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity, specificity, and accuracy of PET/MRI in diagnosing disease flare in Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of inflammatory response to anti-TNF treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of the study vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: WOMAC VAS Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appendicular lean mass (kg) divided by height (meters-squared)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appendicular lean mass divided by body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chromosomal aberration rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Efficacy of the ProLung China Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiovascular (CVD) risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma vasopressin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage reduction in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mullen; Visual Reception Sub-scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mullen; Fine Motor Sub-scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mullen; Receptive Language Subscale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mullen; Expressive Language Sub-scale Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psycho-attitudinal Pattern
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing